Aprea Therapeutics (APRE) Change in Accured Expenses (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Change in Accured Expenses of $218104.0 for Q1 2026, up 1220.16% year-over-year from $16521.0 in Q1 2025, and up 19248.73% quarter-over-quarter from -$1139.0 in Q4 2025.
Aprea Therapeutics (APRE) Change in Accured Expenses (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Change in Accured Expenses for 9 consecutive years, with $218104.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 1220.16% year-over-year to $218104.0; the TTM figure through Mar 2026 stood at $137095.0 (down 74.86% YoY), while the FY2025 annual figure was -$64488.0, up 44.19% from the prior year.
- Change in Accured Expenses rose to $218104.0 in Q1 2026 per APRE's latest filing, from -$1139.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.0 million in Q1 2023 and bottomed at -$1.2 million in Q4 2023.
- Historically, Change in Accured Expenses has averaged -$179711.5 across 5 years, with a median of -$140200.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 281.39% — and 2026, when it jumped 1220.16%.
- Aprea Therapeutics' Change in Accured Expenses stood at -$393192.0 in 2022, then plunged by 198.15% to -$1.2 million in 2023, then soared by 64.61% to -$414928.0 in 2024, then jumped by 99.73% to -$1139.0 in 2025, then jumped by 19248.73% to $218104.0 in 2026.
- Business Quant data shows APRE's Change in Accured Expenses at $218104.0 in Q1 2026, -$1139.0 in Q4 2025, and $60330.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | -82,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -82,000.00 |
| Jun 30, 2026 | -82,000.00 |
| Mar 31, 2026 | 218,104.00 |
| Mar 31, 2026 | 218,104.00 |
| Dec 31, 2025 | -1,139.00 |
| Dec 31, 2025 | -1,139.00 |
| Sep 30, 2025 | 60,330.00 |
| Sep 30, 2025 | 60,330.00 |
| Jun 30, 2025 | -140,200.00 |
| Jun 30, 2025 | -140,200.00 |
| Mar 31, 2025 | 16,521.00 |
| Mar 31, 2025 | 16,521.00 |
| Dec 31, 2024 | -414,928.00 |
| Dec 31, 2024 | -414,928.00 |
| Sep 30, 2024 | 366,857.00 |
| Sep 30, 2024 | 366,857.00 |
| Jun 30, 2024 | 576,957.00 |
| Jun 30, 2024 | 576,957.00 |
| Mar 31, 2024 | -644,427.00 |
| Mar 31, 2024 | -644,427.00 |